Johnson & Johnson under investigation in South Africa over ‘excessive’ drug prices

CAPE TOWN, South Africa (AP) — United States-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug, the country's antitrust regulator said Friday.

J&J's Belgium-based subsidiary Janssen Pharmaceuticals is also under investigation, South Africa's Competition Commission said.

The commission, which regulates business practises, said it opened the investigation this week based on information that the companies “may have engaged in exclusionary practises and excessive pricing” of the tuberculosis drug bedaquiline, which is sold under the brand name Sirturo.

The Competition Commission declined to give further details of its investigation, but health advocacy groups in South Africa say the country is being charged more than twice as much for bedaquiline than other middle- and low-income countries.

Bedaquiline was approved in 2012 and is used to treat drug-resistant TB. 

It is desperately-needed by South Africa, where the infectious disease is the leading cause of death, killing more than 50,000 people in 2021.

South Africa has more than 7 million people living with HIV, more than any other country in the world.

The World Health Organization says that nearly one-third of deaths among people who have HIV/AIDS are due to tuberculosis.

Follow The Gleaner on X, formerly Twitter, and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.